Pacira Pharmaceuticals, Inc. (PCRX)
-NasdaqGS | Prev Close: | 50.85 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 45.00 |
|---|
| Beta: | 1.57 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 15.07 - 52.77 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 376,555 |
|---|
| Market Cap: | 1.69B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.12 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements andEDGAR Online(Tue, Oct 1)
- InPlay: Pacira Pharma announces partnership to support uptake of EXPAREL among the orthopedic marketplace; Five-year arrangement with CrossLink Bioscience follows initial pilot programBriefing.com(Tue, Oct 1)
- Pacira Pharmaceuticals, Inc. Announces Partnership to Support Uptake of EXPAREL® Among the Orthopedic MarketplaceBusiness Wire(Tue, Oct 1)
- Pacira Pharmaceuticals: Slow And Steady Wins The Raceat Seeking Alpha(Fri, Sep 27)
- First Week of May 2014 Options Trading For Pacira Pharmaceuticals (PCRX)at Forbes(Fri, Sep 27)
- Positive Data on Pacira's ExparelZacks(Fri, Sep 20)
- Study Shows EXPAREL® Provided Improved Pain Control, Shorter Length of Hospital Stay and Substantial Cost Savings Following Total Knee ReplacementBusiness Wire(Thu, Sep 19)
- PCRX: Insiders vs. Shortsat Forbes(Mon, Sep 16)
- Insider Trading Alert - Armstrong World Industries And 4 Others Traded By Insidersat TheStreet(Mon, Sep 16)
- Wall Street Transcript Interview with Dr. Christopher M. Starr, the CEO of Raptor Pharmaceutical Corp. (RPTP)Wall Street Transcript(Fri, Sep 13)
- PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements andEDGAR Online(Thu, Sep 12)
- Pacira Pharmaceuticals, Inc. Announces Appointment of Life Sciences Industry Veterans Mark Kronenfeld, M.D., and Dennis Winger to its Board of DirectorsBusiness Wire(Thu, Sep 12)
- PACIRA PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Thu, Aug 15)
- David Abella, Senior Portfolio Manager at Rochdale Investment Management, Interviews with The Wall Street Transcript: A Total-Return Approach to InvestingWall Street Transcript(Thu, Aug 8)
- Narrower-than-Expected Loss at PaciraZacks(Wed, Aug 7)
Key Statistics
| Forward P/E (1 yr): | 145.29 |
|---|
| P/S (ttm): | 35.54 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.72 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.36 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers worldwide.
View More
0.41%